Market Overview

UPDATE: Goldman Sachs Raises PT to $32 on Pfizer on Breakup Optionality

Related PFE
Markets Little Changed Ahead Of 4th Of July Break
Barclays Increases Pfizer Price Target
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

Goldman Sachs maintained Pfizer, Inc. (NYSE: PFE) with a Buy rating and raises the price target from $30.00 to $32.00.

Goldman Sachs commented, "PFE reported 4Q12 earnings and gave 2013 financial guidance which included highlighting efforts to optimize both the innovation-driven and value-based businesses as distinct entities. On the conference call, PFE management described the two businesses as already being distinct in developed markets. While the two businesses are intertwined in Emerging Markets – which works well in these high-growth geographies – PFE will consider separating the two business models in these markets as they evolve. This potential move supports our long held view that PFE could unlock substantially greater value by breaking up the business into two separately traded companies."

Pfizer closed at $27.70 on Tuesday.

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free